The effect of lipid lowering by Acipimox on cardiac and skeletal muscle mitochondrial function.

The effect of lipid lowering by Acipimox on cardiac and skeletal muscle mitochondrial function. - ACP-study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON35239

Enrollment

Registered

2009-10-19

Start date

2010-03-23

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sugar and heartfailure

Interventions

Diabetic ubjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - male - BMI>30kg/m2 - non-insulin dependant type 2 DM or controls - no cardiovascular or DM related diseases - Use of only metformin or SU-derivates

Exclusion criteria

Exclusion criteria: - no contra-indications for MRS - No contra-indications Acipimox - no weight loss/gain last 3 months

Design outcomes

Primary

Measure	Time frame
Main study parameters are the changes in mitochondrial function, lipid accumulation and cardiac function after Acipimox treatment, compared to the placebo treatment group. As secondary endpoints in changes insulin sensitivity, oxidative stress markers and the relationship with the tissue parameter lipid accumulation are considered.	—

Secondary

Measure	Time frame
As secondary endpoints in changes insulin sensitivity, oxidative stress markers and the relationship with the tissue parameter lipid accumulation are considered.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)